Windlas Biotech Limited has successfully concluded its postal ballot process, with shareholders overwhelmingly approving the re-appointment of three directors through special resolutions. The pharmaceutical company announced the results on March 20, 2026, following the completion of remote e-voting that concluded on March 19, 2026.

Director Re-appointments Approved

Shareholders approved three key director re-appointments with requisite majority support:

Voting Results and Participation

The postal ballot process demonstrated strong shareholder support across all three resolutions. The remote e-voting period remained open from February 18, 2026, at 9:00 A.M. to March 19, 2026, at 5:00 P.M.

Resolution-wise Voting Breakdown

All three special resolutions received identical voting results, reflecting unanimous support from participating shareholders:

Resolution 1: Re-appointment of Mr. Ashok Kumar Windlass

• Promoter Group Participation: 13065352 votes (100.00% in favour)
• Public Institutions: 2159125 votes (100.00% in favour)
• Public Non-Institutions: 96406 votes in favour, 2 votes against (99.9979% in favour)

Resolutions 2 & 3: Independent Directors Re-appointment

Both Mr. Vivek Dhariwal and Mr. Gaurav Gulati's re-appointments as Independent Directors received identical voting patterns, with promoter groups not being interested parties in these resolutions as per regulatory requirements.

Regulatory Compliance and Process

The postal ballot was conducted pursuant to Section 110 of the Companies Act, 2013, and related rules. Sandeep Joshi, Practicing Company Secretary, served as the Scrutinizer for the process, ensuring fair and transparent voting procedures.

The company has made the voting results and Scrutinizer's report available on its website at www.windlas.com and on the website of MUFG Intime India Private Limited, the agency that provided e-voting facilities. Company Secretary Ananta Narayan Panda signed the results notification, confirming compliance with Regulation 30 of SEBI Listing Regulations.

Windlas Biotech Limited has announced the allotment of 28,990 equity shares under its employee stock option plans on March 13, 2026. The pharmaceutical company informed both BSE and NSE exchanges about this corporate action through an official communication from Company Secretary and Compliance Officer Ananta Narayan Panda.

Share Allotment Details

The equity shares, each with a face value of Rs.5/-, were allocated across two distinct employee stock option schemes operated by the company:

Regulatory Compliance

The allotment was conducted in accordance with the company's established employee stock option schemes and regulatory requirements. Windlas Biotech has requested both stock exchanges to take this information on record as part of standard compliance procedures.

Company Information

Windlas Biotech Limited operates with its registered office located at 40/1, Mohabewala Industrial Area, Dehradun, Uttarakhand, and maintains its corporate office in Gurgaon, Haryana. The company trades on BSE under code 543329 and on NSE under the symbol WINDLAS.

The WBL Employee Stock Option Scheme 2023 accounted for the majority of the current allotment, representing approximately 86% of the total shares allocated. This employee stock option allotment reflects the company's ongoing commitment to employee participation in equity ownership through structured compensation plans.